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Simon Bossart1,2* , Konrad Mühlethaler2, Christian Garzoni3,4 and Hansjakob Furrer3
Abstract 
Objectives: In this study, we compared IFA and real-time PCR in bronchoalveolar lavage specimens of HIV infected 
patients. A total of 66 BALs from 62 HIV patients were included in the study. 30 IFA positive and 36 IFA negative speci-
mens were tested with real-time PCR, targeting the major surface glycoprotein. We performed a retrospective analysis 
of the patient’s medical records, compared the results of the IFA and PCR tests and analyzed costs, expenditure of 
time and personal expenses.
Results: All of the 30 IFA positive samples were PCR positive. 35 of 36 IFA negative probes were also negative in the 
PCR assay. Considering the PCR results as a binary outcome (positive/negative) sensitivity was 100%, specificity 97.2%. 
The patient with negative IFA and positive PCR had a clear clinical picture of PCP and responded to PCP treatment. 
PCR was more than twice as expensive and time-consuming as IFA. Diagnostic accuracy for PCP of PCR and IFA was 
comparable in HIV-infected patients, but IFA was significantly less expensive and less time-consuming. Therefore, IFA 
testing can continue to be used as gold standard in the diagnosis of PCP in HIV patients. However, in special cases, IFA 
may lack sensitivity and PCR should be added to the diagnostic armamentarium.
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Introduction
Pneumocystis jirovecii, an opportunistic fungal pathogen, 
can cause severe interstitial pneumonia (Pneumocystis 
pneumonia, PCP) in immunocompromised individuals 
(HIV and non-HIV individuals) [1, 2].
At present, in the absence of lung biopsy histology, 
immunofluorescence assay (IFA) of bronchoalveolar fluid 
(BAL) and induced sputum is considered the gold stand-
ard in diagnosing P. jirovecii [3].
IFA may lack of sensitivity in immunocompromised 
non-HIV like oncological and rheumatological patients 
when Pneumocystis load is low. In these respiratory 
samples IFA may be either negative or show artefacts 
[4]. Therefore, more sensitive PCR based methods were 
introduced which showed limitations in specificity. Speci-
mens of asymptomatic immunocompromised individuals 
with low Pneumocystis load may yield a positive PCR sig-
nal while microscopic examination is negative—probably 
representing colonization. Notably, these discrepancies 
were observed in several reports in non-HIV-infected 
patients [4, 5] and cut-off values of quantitative PCR were 
tried to be established to differentiate between coloniza-
tion and infection [6]. In this study we evaluate a quan-
titative real-time PCR for the detection of P. jirovecii in 
Open Access
BMC Research Notes
*Correspondence:  simon.bossart@insel.ch
1 Department of Dermatology, University Hospital Inselspital, 3010 Bern, 
Switzerland
Full list of author information is available at the end of the article
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
14
39
69
 
| 
do
wn
lo
ad
ed
: 
13
.5
.2
02
0
Page 2 of 5Bossart et al. BMC Res Notes          (2020) 13:235 
BAL fluids of HIV patients and compare PCR with con-
ventional immunofluorescence assay to establish a cut-off 
value to distinguish between colonization and Pneumo-
cystis infection. We performed retrospective chart review 
and compared costs, expenditure of time and personal 
expenses of PCR and IFA.
Main text
Methods
A total of 66 bronchoalveolar lavage specimen from 
62 HIV patients obtained between 1998 and 2009 were 
enrolled in this retrospective study. 3 BAL samples from 
3 patients had to be excluded in the absence of sufficient 
available material. The 63 BALs from the remaining 59 
patients were included in our study.
The BALs were performed in the Bern University 
Hospital following a standardized protocol: 150  ml of 
sterile saline solution was instilled within the bronchial 
trees and recovered in three fractions. For Pneumocys-
tis diagnostics, samples of 10 ml native BAL liquid were 
centrifuged and used for IFA diagnostics. The remaining 
material was frozen at −80 °C.
MONOFLUO™ P. jirovecii IFA Test Kit was used as 
gold standard for the routine diagnostics of P. jirovecii. 
The test kit consists of a commercially available murine 
monoclonal antibody, labeled with fluorescein isothio-
cynate that reacts with all forms of Pneumocystis stages. 
Specimen holders were scanned by two independent 
investigators with 400 × magnification in a light micro-
scope (Zeiss Axiophot).
Semi-quantitative microscopy was performed for 
each sample (number of asci or trophic forms per field 
of vision: − = absent, + = < 1 (few), ++ = 1–10 (many), 
+++ = > 10 (abundant). The sensitivity of this IFA is 
close to 100% and the specificity is about 95.8% according 
to the manufacturer [7].
For the PCR procedures, nucleic acids were extracted 
from 25ul of BAL pellets using automated  NucliSense® 
easy MAG™ platform (bioMérieux, Switzerland). A real-
time PCR was used targeting the major surface glyco-
protein (MSG) gene based on the work of Linssen, 2006 
[8]. The real-time PCR reaction contained 5  µl of puri-
fied DNA, 0.6  µl of each primer PCPFor and PCPRev, 
0.15  µM PCPProbe, 1xTaqMan Universal Master Mix 
(ABI), 1x Exo IPC Mix (ABI) and 1x Exo IPC DNA (ABI). 
Each DNA sample was analyzed in duplication following 
an amplification protocol performed on an ABI PRISM 
7000 Sequence Detection system (ABI).
Each cycle consists of 2 min at 50 °C (digestion of pre-
vious amplification products), 10  min at 95  °C (enzyme 
inactivation and polymerase activation), followed by 
42 cycles of 15 s at 95  °C and 60 s at 60  °C. As positive 
controls different plasmid concentrations containing a 
P. jirovecii major surface glycoprotein gene (MSG) insert 
was used and linearized  2x105,  2x104,  2x103,  103,  2x102, 
and  102 copies per reaction to generate a standard curve. 
Three negative controls were included in each run. (1) 
water, (2) 10x Exo IPC Block (Applied Biosystems (ABI) 
Foster City, CA, USA; NAC = no amplification control), 
and a negative extraction control. In order to detect 
inhibitors in the specimens, an EXO IPC DNA (ABI) was 
included in each Real-time PCR reaction. The quantifica-
tion of the Pneumocystis DNA was illustrated by the cycle 
threshold (Ct) and the number of copies/ml. Because 
the MSG gene consists of 50 to 100 copies, all our PCR 
results are based on the mean quantity with 50 cop-
ies/genome. A sample was interpreted as positive if the 
duplicates were positive. A retest of the sample was per-
formed if only one result was positive. If this retest was 
again positive, the sample was considered positive for P. 
jirovecii. A negative sample was interpreted as confirmed 
negative when EXO IPC DNA (ABI) results excluded 
inhibitor in the specimen.
To determine the PCR detection limit of the IFA we 
selected a strongly IFA-positive patient with more than 
ten asci/trophic forms per field of vision (+++) in the 
semi-quantitative microscopy and performed a ten-
fold dilution series (log10). The detection limit was 190 
copies/ml or 35 cycles. To compare the diagnostic per-
formance of the two tests (IFA and real-time PCR), a 
Receiver Operating Characteristic curve analysis (ROC) 
was performed.
Data of the performed retrospective analysis of the 
patient’s medical records was analyzed by using the 
Stata™ 10 for Windows, StataCorp., USA: Bivariate anal-
ysis (Pearson’s Chi square test or trend Chi square), odds 
ratios, 95% confidence intervals and multivariate analysis 
were performed.
The medical history of all 62 patients were reviewed 
retrospectively focusing on age, sex, clinical symptoms 
(fever, cough, dyspnea), imaging studies, HIV back-
ground (CD4 counts, viral load, cART), laboratory analy-
sis (LDH), PCP-Prophylaxis before BAL, PCP-Therapy 
after BAL and outcome. The retrospective data analysis 
was approved by the cantonal ethic commission of Bern.
Results
All of the 30 IFA-positive BAL samples also tested posi-
tive by PCR. The pathogen load ranged from 698 copies/
ml to 2,440,000 copies/ml. Among the 36 IFA-negative 
BAL probes, 35 were PCR negative. The fungal burden 
(number of asci or trophic formsper field of vision) cor-
related well with the PCR results. Only one IFA-negative 
BAL specimen yielded a positive PCR result. It contained 
the lowest Pneumocystis load (297 copies/ml) of all BALs 
tested positive (Fig. 1).
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Considering the PCR results as a binary outcome (posi-
tive/negative), sensitivity was 100%, specificity 97.2%. 
The area under the ROC curve was 0.99.
The data of the reviewed medical history are shown in 
Table  1. No significant differences in age and sex were 
found in the IFA-negative and positive group and the 
clinical symptoms were similar.
Patients with positive IFA had similar viral loads at the 
last measurement before BAL, but lower CD4 counts and 
were less likely to be on combination antiretroviral ther-
apy (cART). Patients with positive IFA had higher LDH 
levels. They were less likely to be on anti- PCP prophy-
laxis and more likely to be started on PCP treatment as 
shown in Table 1.
The single patient with the discrepant result (IFA-/
PCR +) was examined in more detail. The medical his-
tory of this patient revealed that the patient had a chronic 
obstructive pulmonary disease (COPD) and was on 
antiretroviral therapy with current CD4 counts of 150 
cells/µL and plasma HIV RNA of 22 copies/ml. He had 
the typical clinical features PCP with fever and dyspnea 
for several days and abnormal O2 saturation. CT scan 
showed marked ground glass opacities in all lung fields. 
In BAL no other reason for the pneumonitis was found 
and he responded to a 3 weeks course of trimethoprim/
sulfamethoxazole. Based on this the patient was consid-
ered to have suffered of PCP.
Additional analyses concerning costs, time and per-
sonal expenses were performed. One immunofluores-
cence test costs CHF 23.80 while one real time-PCR is 
CHF 63 (ratio PCR/IFA = 2.6). Results of the IFA test is 
available within2 h, PCR including DNA extraction takes 
4.5  h (ratio PCR/IFA = 2.25). Although IFA can easily 
be performed in small laboratories with a fluorescence 
microscope, interpretation of the IFA test may be diffi-
cult due to artefacts which can easily be mixed-up with 
trophic forms or asci. Therefore, skilled staff is needed 
to obtain correct results. For the PCR tests including 
DNA extraction large laboratories with accurate hard-
ware (DNA extraction machine, thermocycler etc.) are 
needed but usually they are performed during day-time 
on working days only, limiting the real-life availability. 
The interpretation of the test result can be done without 
any special training.
Discussion
Previous publications report a discrepancy between neg-
ative immunofluorescence and positive PCR results in 
immunocompromised non-HIV-infected patients with 
better sensitivity and specificity in the PCR assay com-
pared to conventional, microscopic examinations [9, 10].
We could not find such a discrepancy in HIV-infected 
patients in the present study. We found a very good cor-
relation in 97.2% of all 66 tested BAL specimens in 62 
HIV patients. Only one specimen yielded a discrepant 
result: IFA was negative and PCR revealed a positive sig-
nal, corresponding to the lowest Pneumocystis load (298 
copies/ml) of all tested BALs. The patients clinical and 
radiological findings and the response to PCP treatment 
was well compatible with PCP and based on this we did 
not consider this discrepant result as false positive. This 
patient was also known to have COPD as another lung 
disease. One could speculate that in this patient on viro-
logically successful cART but CD4 counts below 200 
cells/µL a lower fungal burden was associated with PCP 
partly also explained by COPD which has been associ-
ated with a higher risk for Pneumocystis colonization and 
higher risk of PCP in AIDS patients [11, 12]. This could 
explain our discrepant result.
Since we did not find false positive PCR results it was 
not possible to establish cut-off value for our quantitative 
PCR assay. In other words and in discrepancy with non-
HIV immunocompromesed patients, a positive PCR with 
a compatible clinic should always be conceded diagnostic 
for PCP and lead to an appropriate therapy.
However, it must be taken into account that coloni-
zation of Pneumocystis can also occur in HIV-infected 
patients, as numerous studies have shown [13, 14].
The review of the medical records revealed lower 
CD4 + counts, lower rate of cART and PCP-prophylaxis 
Fig. 1 Comparison between IFA (number of asci or trophic forms 
per field of vision) and PCR (copies/ml) of all tested BAL samples. One 
specimen with a discrepant result with negative IFA and positive low 
copies PCR (297 copies/ml) showed in the red circle
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and higher LDH-levels in the IFA-positive group com-
pared with the IFA-negative specimens. Those patients 
have therefore stronger evidences for the presence of the 
infection with Pneumocystis jirovecii.
This study shows that both IFA and PCR have a high 
sensitivity for Pneumocystis detection in AIDS patients 
with PCP. Some studies found a lower sensitivity of IFA in 
HIV-negative individuals with PCP. These findings can be 
explained by the higher fungal loads in HIV-infected PCP 
patients compared to PCP patients with other immuno-
deficiencies [15, 16]. Due to the comparable diagnostic 
accuracy of PCR and IFA in our study, we also examined 
their cost-effectiveness and we could show that, in our 
setting, real-time PCR is three times as expensive and 
performance takes twice as long as the IFA assay. The 
benefit of the IFA is the handiness of this method that 
can be easily performed in small laboratories if a fluo-
rescence microscope with appropriate filter is available. 
The equipment needed to run a PCR is expensive (DNA 
extraction machine, thermocycler etc.) and logistic issue 
commonly limited its use during daytime on working 
days. On the other hand, performing IFA requires special 
training while PCR does not.
Conclusions
In summary, our findings show that PCR and IFA both 
are accurate diagnostic tools in HIV-infected patients. 
But IFA is clearly more effective regarding logistic issues 
and expenditure of time and cost. However, in special 
cases like in patients with low fungal burden and high 
risk for PCP, IFA may lack sensitivity. Therefore, PCR 
should be added in the diagnostic armamentarium of 
every specialized laboratory.
Limitations
However, our study has several limitations. The data were 
analysed retrospectively and the study population was 
rather small. This has to do with the fact, that the inci-
dence of PCP has massively declined since introduction 
of cART.
The fact that we did not find any colonized patients 
might be related to the rather small number of cases in 
our retrospective study. As mentioned in the discussion, 
larger studies have found colonization of Pneumocystis 
also in HIV positive patients.
A potential weakness of the IFA is the lack of sensitivity 
when fungal load is low. Therefore, interpretation of the 
Table 1 Detailed patient characteristics of the 62 HIV-positive patients
Data presented as median (IQR), n (%)
IF immunofluorescence, PCP pneumocystis pneumonia, BAL bronchoalveolar lavage
62 HIV positive patients 66 Bronchoalveolar lavage Statistical 
significance
Characteristics Group 1: IF positive Group 2: IF negative
Subjects 30 36
Age years (median, IQR) 41 (34.5–50.5) 41.5 (33.7–48) ns
Male/female 21/9 23/13 ns
HIV background
 CD4 + counts/ml (median, IQR) 39 (11.5– 65) 104.5 (22.7–190) s
 Viral load copies/ml (median, IQR) 189,058 (84,818.7–671,206.5) 180,009 (43,062.5–745,879.2) ns
 cART (%) 3 (10%) 26 (72.2%) s
Symptoms between hospitalisation and BAL
 Fever 19 (63.3) 22 (61.1) ns
 Cough 25 (83.3) 32 (88.8) ns
 Dyspnea 20 (66.6) 15 (41.6) ns
Laboratory analysis
 LDH (U/l) 588.5 (506.7–854.5) 463.5 (384.2–542.5) s
Outcome
 In hospital death 1 (3.3) 2 (5.5) ns
Therapy/prophylaxis
 PCP-Prophylaxis before BAL 2 (6.6) 13 (36.1) s
 PCP-Therapy after BAL 30 (100) 14 (38.8) s
PCR Pneumocystis results
 Amount of positive qualitative PCR results 30 (100) 1 (2.7) s
Positive quantitative PCR copies/ml (median, IQR) 506,068.59 (141,239.7–783,667.2) 298 s
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IFA test may be difficult due to artefacts which can easily 
be mixed-up with trophic forms or asci.
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